Android app Apple app link

Corcept's Phase III trial of ovarian cancer therapy shows PFS improvement

By Yahoo! Finance   |   4 days ago
Corcept's Phase III trial of ovarian cancer therapy shows PFS improvement

Corcept Therapeutics' Phase III ROSELLA trial combining oral relacorilant with nab-paclitaxel for platinum-resistant ovarian cancer met its primary endpoint of improved progression-free survival.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.